Document is current
Any future updates will be listed below
-
Authors
Malone, Eoghan R.
Oliva, Marc
Sabatini, Peter J. B.
Stockley, Tracy L.
Siu, Lillian L.
- License Information
-
More Information
Article History
Received: 20 September 2019
Accepted: 4 December 2019
First Online: 14 January 2020
Competing interests
: LLS is a consultant for Merck (compensated), Pfizer (compensated), Celgene (compensated), AstraZeneca/Medimmune (compensated), Morphosys (compensated), Roche (compensated), GeneSeeq (compensated), Loxo (compensated), Oncorus (compensated), Symphogen (compensated), Seattle Genetics (compensated), GSK (compensated), Voronoi (compensated), and Treadwell Therapeutics (compensated). She has received grants or research support from Novartis, Bristol-Myers Squibb, Pfizer, Boehringer-Ingelheim, GlaxoSmithKline, Roche/Genentech, Karyopharm, AstraZeneca/Medimmune, Merck, Celgene, Astellas, Bayer, Abbvie, Amgen, Symphogen, Intensity Therapeutics, Mirati, Shattucks, and Avid. Her spouse holds stock in Agios.MO is a consultant for Bristol-Myers Squibb (compensated).TLS is a consultant for Astra Zeneca, Amgen, Astellas, Janssen, and Bristol Myers Squibb.The remaining authors declare that they have no competing interests.